Immune Technology Corp

Executive Summary

Immune Technology Corp is a private immunology and infectious disease company based in New York, founded in 2018. The company is focused on developing innovative vaccines and immunotherapies, with a particular emphasis on addressing unmet needs in infectious diseases such as influenza. Recent WHO recommendations for the 2026 southern hemisphere influenza vaccine composition highlight the ongoing relevance of the company's potential pipeline, which may include candidates targeting the identified strains (e.g., H1N1, H3N2, and B/Victoria lineages). While specific product details and clinical programs are not publicly disclosed, the company's positioning in the infectious disease space suggests a strategic focus on seasonal and pandemic preparedness. As a private entity with limited publicly available information, Immune Technology's progress is closely tied to future funding, partnership announcements, and regulatory updates.

Upcoming Catalysts (preview)

• Q2 2026Partnership or licensing agreement for influenza vaccine technology30% success
• Q3 2026Series A or seed funding round completion40% success
• TBDPublication of preclinical or early clinical data for lead candidate20% success